greeksoup/ stocks
Stocks / India / DRREDDY / Q2 FY2024

Dr. Reddy's Laboratories Ltd. Q2 FY2024 results: revenue ₹6,903 crore, up 9.0% on the year

Dr. Reddy's Laboratories Ltd. (DRREDDY) reported consolidated revenue from operations of ₹6,903 crore for Q2 FY2024, the quarter ended 30 September 2023, up 9.0% on the same quarter a year earlier. Profit after tax was ₹1,482 crore, up 33.0% on the year, and earnings per share ₹89.09. The figures are the company's own, from the unaudited results it filed with NSE on 27 October 2023.

Revenue from operations₹6,903 croreup 9.0%
Profit after tax₹1,482 croreup 33.0%
EPS₹89.09
QuarterQ2 FY2024ended 30 September 2023

The quarter, against the one before and a year earlier

LineQ2 FY2024Quarter beforeA year earlierChange on the year
Revenue from operations6,903n/an/an/a
Other income315n/an/an/a
Total income7,218n/an/an/a
Cost of materials consumed956n/an/an/a
Purchases of stock-in-trade1,138n/an/an/a
Changes in inventories-91n/an/an/a
Employee benefit expense1,280n/an/an/a
Finance costs35n/an/an/a
Depreciation, depletion and amortisation376n/an/an/a
Other expenses1,611n/an/an/a
Total expenses5,305n/an/an/a
Profit before exceptional items and tax1,912n/an/an/a
Exceptional items0n/an/an/a
Profit before tax1,912n/an/an/a
Current tax590n/an/an/a
Deferred tax-156n/an/an/a
Total tax434n/an/an/a
Profit after tax1,482n/an/an/a
Attributable to owners of the parent0n/an/an/a
Other comprehensive income-113n/an/an/a
Total comprehensive income1,369n/an/an/a
EPS, basic₹89.09n/an/an/a
EPS, diluted₹88.91n/an/an/a

₹ crore except per share.

Quarterly results, the last 12 quarters

Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027
Sales6,9037,2377,1147,6968,0388,3818,5288,5728,8288,7537,5468,100
Expenses5,3055,6275,7106,0076,4346,6617,0516,9587,4147,4817,8277,902
Operating profit2,0082,0231,8312,1302,0762,2731,9982,1742,0101,887382860
OPM %29%28%26%28%26%27%23%25%23%22%5%11%
Other income315216198187308150522290324269475355
Interest35395960768266839194106126
Depreciation376374368381397471455476505521557537
Exceptional items000000000000
Profit before tax1,9121,8261,6021,8771,9111,8702,0001,9051,7381,541195552
Tax %23%25%18%26%30%25%21%26%23%23%-11%21%
Net profit1,4821,3811,3101,3921,3421,4041,5871,4101,3371,190221436
EPS in ₹₹89.09₹82.94₹78.66₹83.61₹15.08₹16.97₹19.12₹17.04₹16.18₹14.53₹2.65₹5.33
FilingNSENSENSENSENSENSEFilingFilingFilingFilingFilingFiling

₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company. EPS is as filed for each quarter. A split or a bonus issue changes the share count, so quarters before it are on the old count.

Source

Unaudited consolidated results for the quarter ended 30 September 2023, filed with NSE on 27 October 2023: the result statement. All of Dr. Reddy's Laboratories Ltd.'s results: NSE company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install